Prescription Dermatology
Tapinarof (VTAMA)
Novel AhR agonist topical therapy for psoriasis and AD
Duration
topical1 days1 sessions
Downtime
なし
Sessions
8～12 weeksで効果判定
About This Treatment
Tapinarof is an aryl hydrocarbon receptor (AhR) agonist topical therapy used in psoriasis and atopic dermatitis, offering a nonsteroidal option.
Mechanism of Action
By modulating AhR signaling, it downregulates inflammatory pathways and supports barrier-related skin biology.
Indications
General indication (see detailed description)
Expected Results
PSOARING phase 3 studies met primary endpoints, and newer phase 3 AD studies reported efficacy with acceptable tolerability.
Clinical Evidence
Lebwohl M, et al. (2021)
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med
Clinical improvement was reported in this study (see original paper for details).
Stein Gold L, et al. (2025)
Tapinarof in two phase 3 atopic dermatitis trials. J Dermatolog Treat
Clinical improvement was reported in this study (see original paper for details).
U.S. FDA (2024)
VTAMA prescribing information. FDA label
Clinical improvement was reported in this study (see original paper for details).
Risks & Side Effects
Folliculitis, contact dermatitis, headache, and local irritation are reported. Adjust use by treated area and skin tolerance.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition